https://edgen.pre.edgen.tech/zh-tw/news/post/workday-surges-14-after-q1-earnings-revenue-beat-estimates2026-05-21T22:25:45.060Zdaily1Edgen Stockzh-Hant2026-05-21T22:25:45.060+00:00Workday 第一財季營收與盈利雙雙超預期，股價大漲 14%https://static.edgen.tech/news/images/workday-surges-14-after-q1-earnings-revenue-beat-estimates-20260521.pngWorkday 第一財季營收與盈利雙雙超預期，股價大漲 14% https://edgen.pre.edgen.tech/zh-tw/news/post/veracyte-to-present-data-from-2-phase-iii-cancer-trials-at-asco-20262026-05-21T22:25:19.656Zdaily1Edgen Stockzh-Hant2026-05-21T22:25:19.656+00:00Veracyte 將在 2026 年 ASCO 年會上展示兩項 III 期癌症試驗數據https://static.edgen.tech/news/images/veracyte-to-present-data-from-2-phase-iii-cancer-trials-at-asco-2026-20260521.pngVeracyte 將在 2026 年 ASCO 年會上展示兩項 III 期癌症試驗數據 https://edgen.pre.edgen.tech/zh-tw/news/post/aktis-aky-2519-shows-404-suvmax-uptake-in-first-human-cancer-trial2026-05-21T22:00:37.454Zdaily1Edgen Stockzh-Hant2026-05-21T22:00:37.454+00:00Aktis 的 AKY-2519 在首次人體癌症試驗中顯示 40.4 SUVmax 攝取https://static.edgen.tech/news/images/aktis-aky-2519-shows-404-suvmax-uptake-in-first-human-cancer-trial-20260521.pngAktis 的 AKY-2519 在首次人體癌症試驗中顯示 40.4 SUVmax 攝取 https://edgen.pre.edgen.tech/zh-tw/news/post/zoom-raises-fy2027-forecast-to-over-5-billion-on-ai-demand2026-05-21T21:59:44.447Zdaily1Edgen Stockzh-Hant2026-05-21T21:59:44.447+00:00Zoom 受 AI 需求推動將 2027 財年指引上調至逾 50 億美元https://static.edgen.tech/news/images/zoom-raises-fy2027-forecast-to-over-5-billion-on-ai-demand-20260521.pngZoom 受 AI 需求推動將 2027 財年指引上調至逾 50 億美元 https://edgen.pre.edgen.tech/zh-tw/news/post/nuvalent-to-show-40-response-rate-for-zidesamtinib-pivotal-lung-cancer-data-at-asco2026-05-21T21:59:20.930Zdaily1Edgen Stockzh-Hant2026-05-21T21:59:20.930+00:00Nuvalent將在ASCO展示zidesamtinib 40%的緩解率及肺癌關鍵數據https://static.edgen.tech/news/images/nuvalent-to-show-40-response-rate-for-zidesamtinib-pivotal-lung-cancer-data-at-asco-20260521.pngNuvalent將在ASCO展示zidesamtinib 40%的緩解率及肺癌關鍵數據 https://edgen.pre.edgen.tech/zh-tw/news/post/amex-exploration-secures-c59-million-to-fund-perron-gold-project2026-05-21T21:56:33.422Zdaily1Edgen Stockzh-Hant2026-05-21T21:56:33.422+00:00Amex Exploration 獲得 0.59 億加元資金用於 Perron 黃金項目https://static.edgen.tech/news/images/amex-exploration-secures-c59-million-to-fund-perron-gold-project-20260521.pngAmex Exploration 獲得 0.59 億加元資金用於 Perron 黃金項目 https://edgen.pre.edgen.tech/zh-tw/news/post/turkish-stocks-plunge-6-after-court-ousts-opposition-leader2026-05-21T21:38:28.265Zdaily1Edgen Stockzh-Hant2026-05-21T21:38:28.265+00:00法院罷免反對黨領袖後 土耳其股市暴跌 6%https://static.edgen.tech/news/images/turkish-stocks-plunge-6-after-court-ousts-opposition-leader-20260521.png法院罷免反對黨領袖後 土耳其股市暴跌 6% https://edgen.pre.edgen.tech/zh-tw/news/post/black-diamond-rises-on-152-month-cancer-trial-result2026-05-21T21:33:26.470Zdaily1Edgen Stockzh-Hant2026-05-21T21:33:26.470+00:00Black Diamond 股價因 15.2 個月癌症試驗結果大漲https://static.edgen.tech/news/images/black-diamond-rises-on-152-month-cancer-trial-result-20260521.pngBlack Diamond 股價因 15.2 個月癌症試驗結果大漲 https://edgen.pre.edgen.tech/zh-tw/news/post/why-a-9010-portfolio-may-be-better-than-6040-for-some-investors2026-05-21T21:32:58.265Zdaily1Edgen Stockzh-Hant2026-05-21T21:32:58.265+00:00為什麼 90/10 投資組合對某些投資者來說可能優於 60/40https://static.edgen.tech/news/images/why-a-9010-portfolio-may-be-better-than-6040-for-some-investors-20260521.png為什麼 90/10 投資組合對某些投資者來說可能優於 60/40 https://edgen.pre.edgen.tech/zh-tw/news/post/merck-lung-cancer-combo-with-kelun-hits-70-response-rate2026-05-21T21:32:56.238Zdaily1Edgen Stockzh-Hant2026-05-21T21:32:56.238+00:00默沙東與科倫博泰肺癌聯合療法客觀緩解率達 70%https://static.edgen.tech/news/images/merck-lung-cancer-combo-with-kelun-hits-70-response-rate-20260521.png默沙東與科倫博泰肺癌聯合療法客觀緩解率達 70% https://edgen.pre.edgen.tech/zh-tw/news/post/imax-surges-15-on-reports-of-a-potential-sale2026-05-21T21:30:24.830Zdaily1Edgen Stockzh-Hant2026-05-21T21:30:24.830+00:00IMAX 傳出考慮出售消息，股價飆升 15%https://static.edgen.tech/news/images/imax-surges-15-on-reports-of-a-potential-sale-20260521.pngIMAX 傳出考慮出售消息，股價飆升 15% https://edgen.pre.edgen.tech/zh-tw/news/post/bicara-cancer-drug-doubles-survival-rate-to-31-in-head-and-neck-trial2026-05-21T21:29:39.219Zdaily1Edgen Stockzh-Hant2026-05-21T21:29:39.219+00:00Bicara抗癌藥物在頭頸癌試驗中將生存率翻倍至31%https://static.edgen.tech/news/images/bicara-cancer-drug-doubles-survival-rate-to-31-in-head-and-neck-trial-20260521.pngBicara抗癌藥物在頭頸癌試驗中將生存率翻倍至31% https://edgen.pre.edgen.tech/zh-tw/news/post/syndax-to-present-new-revuforj-data-from-4-leukemia-trials-at-asco2026-05-21T21:28:58.831Zdaily1Edgen Stockzh-Hant2026-05-21T21:28:58.831+00:00Syndax 將在 ASCO 展示 Revuforj 治療白血病的 4 項臨床試驗新數據https://static.edgen.tech/news/images/syndax-to-present-new-revuforj-data-from-4-leukemia-trials-at-asco-20260521.pngSyndax 將在 ASCO 展示 Revuforj 治療白血病的 4 項臨床試驗新數據 https://edgen.pre.edgen.tech/zh-tw/news/post/remix-drug-shows-43-response-rate-in-rare-cancer-trial2026-05-21T21:26:22.609Zdaily1Edgen Stockzh-Hant2026-05-21T21:26:22.609+00:00Remix 藥物在罕見癌症試驗中顯示出 43% 的緩解率https://static.edgen.tech/news/images/remix-drug-shows-43-response-rate-in-rare-cancer-trial-20260521.pngRemix 藥物在罕見癌症試驗中顯示出 43% 的緩解率 https://edgen.pre.edgen.tech/zh-tw/news/post/akaris-cancer-drug-shows-high-synergy-with-kras-inhibitors2026-05-21T21:26:17.221Zdaily1Edgen Stockzh-Hant2026-05-21T21:26:17.221+00:00Akari 癌症藥物與 KRAS 抑制劑顯示高度協同作用https://static.edgen.tech/news/images/akaris-cancer-drug-shows-high-synergy-with-kras-inhibitors-20260521.pngAkari 癌症藥物與 KRAS 抑制劑顯示高度協同作用 https://edgen.pre.edgen.tech/zh-tw/news/post/dow-surges-351-points-to-new-record-as-investors-rotate-to-tech2026-05-21T21:25:29.445Zdaily1Edgen Stockzh-Hant2026-05-21T21:25:29.445+00:00道指飆升 351 點創下新紀錄，投資者向科技股調倉https://static.edgen.tech/news/images/dow-surges-351-points-to-new-record-as-investors-rotate-to-tech-20260521.png道指飆升 351 點創下新紀錄，投資者向科技股調倉 https://edgen.pre.edgen.tech/zh-tw/news/post/seer-rejects-radoff-jecs-240-per-share-takeover-bid2026-05-21T20:56:36.408Zdaily1Edgen Stockzh-Hant2026-05-21T20:56:36.408+00:00Seer 拒絕 Radoff-JEC 每股 2.40 美元的收購報價https://static.edgen.tech/news/images/seer-rejects-radoff-jecs-240-per-share-takeover-bid-20260521.pngSeer 拒絕 Radoff-JEC 每股 2.40 美元的收購報價 https://edgen.pre.edgen.tech/zh-tw/news/post/lucid-group-faces-fraud-inquiry-after-revenue-miss-sinks-stock-72026-05-21T20:55:35.624Zdaily1Edgen Stockzh-Hant2026-05-21T20:55:35.624+00:00Lucid Group 因營收不及預期導致股價大跌 7%，現面臨欺詐調查https://static.edgen.tech/news/images/lucid-group-faces-fraud-inquiry-after-revenue-miss-sinks-stock-7-20260521.pngLucid Group 因營收不及預期導致股價大跌 7%，現面臨欺詐調查 https://edgen.pre.edgen.tech/zh-tw/news/post/baycom-stock-drops-11-as-law-firm-probes-executive-exodus2026-05-21T20:55:26.034Zdaily1Edgen Stockzh-Hant2026-05-21T20:55:26.034+00:00BayCom 股價因律師事務所調查高管離職而下跌 11%https://static.edgen.tech/news/images/baycom-stock-drops-11-as-law-firm-probes-executive-exodus-20260521.pngBayCom 股價因律師事務所調查高管離職而下跌 11% https://edgen.pre.edgen.tech/zh-tw/news/post/carmax-faces-investor-investigation-after-stock-plunges-152026-05-21T20:55:23.259Zdaily1Edgen Stockzh-Hant2026-05-21T20:55:23.259+00:00CarMax 股價暴跌 15% 後面臨投資者調查https://static.edgen.tech/news/images/carmax-faces-investor-investigation-after-stock-plunges-15-20260521.pngCarMax 股價暴跌 15% 後面臨投資者調查